FDA clears IND for Centessa's ORX142, Phase 1 study in sleep-deprived volunteers planned

Centessa Pharmaceuticals plc

FDA cleared IND for ORX142, a novel OX2R agonist for neurological/neurodegenerative disorders.
Phase 1 study will evaluate safety, PK, and PD (MWT, KSS) in acutely sleep-deprived healthy adults.
Clinical data from Phase 1 expected this year; study initiation imminent.
ORX142 is second orexin franchise candidate; ORX750 in Phase 2a for narcolepsy/IH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.